This section features all recent CSL Behring news releases. Click the tabs to select releases in your area of interest. Click Resources to find additional background material on CSL Behring.
CSL Behring continues legacy of support for Alpha-1 Community with Global Research Conference and Patient Congress Sponsorship.
CSL Behring’s RAPID Extension Study data confirms disease-modifying effect of Respreeza® in patients with AATD.
CSL Behring is hosting an Expert Forum "Modifying Alpha-1 Antitrypsin Deficiency Related Emphysema" today during the 26th International Congress of the European Respiratory Society (ERS) in London.